Please provide us with documentation of your trading history in the Company’s stock by emailing a relevant copies of your brokerage statements to If you have any questions or need assistance, please call us at (212) 308-5858. In making this agreement, BESPC is relying upon your representation that you held the Company’s shares on and that you continue to hold Company shares. BESPC has conducted an investigation and believes that there is a valid basis to assert claims against the Company and its directors and/or officers for breach of fiduciary duties and other applicable laws. (“BESPC”) to represent you in connection with potential litigation against Silverback Therapeutics (the “Company”) and its directors and officers arising out of the. This will confirm that you have retained Bragar Eagel & Squire, P.C. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Silverback’s stockholders.
The deal is scheduled to close in the fourth quarter of 2022.īragar Eagel & Squire is concerned that Silverback’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Pursuant to the merger agreement, Silverback equity holders are expected to own approximately 37% of the combined company. On July 21, 2022, Silverback announced that it had entered into an agreement to be acquired by ARS in an all-cash deal valued at $265M. (NASDAQ: SBTX) (“Silverback”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by ARS Pharmaceuticals, Inc.
NEW YORK, J– Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Silverback Therapeutics, Inc.
0 kommentar(er)
